Superselective Ophthalmic Artery Chemotherapy as Primary Treatment for Retinoblastoma (Chemosurgery)

• Published in: Ophthalmology (Rochester, Minn.) Vol. 117; no. 8; pp. 1623 - 1629
• Main Authors: Abramson, David H., MD, Dunkel, Ira J., MD, Brodie, Scott E., MD, PhD, Marr, Brian, MD, Gobin, Y. Pierre, MD
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.08.2010
• Subjects: Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Carboplatin - administration & dosage; Carboplatin - adverse effects; Child; Child, Preschool; Electroretinography; Female; Fluorescein Angiography; Follow-Up Studies; Humans; Infant; Infusions, Intra-Arterial; Male; Melphalan - administration & dosage; Melphalan - adverse effects; Ophthalmic Artery - drug effects; Ophthalmology; Prospective Studies; Retinal Neoplasms - drug therapy; Retinal Neoplasms - pathology; Retinoblastoma - drug therapy; Retinoblastoma - pathology; Topotecan - administration & dosage; Topotecan - adverse effects; Treatment Outcome; Visual Acuity

Purpose To report on our 3-year experience with the use of superselective ophthalmic artery infusion of chemotherapy as initial, primary treatment for intraocular retinoblastoma. Design Prospective, institutional review board-approved clinical trial. Participants Twenty-eight eyes of 23 newly diagno...